Follicular Lymphoma: Refining Prognostic Models and Impact of Pod-24 in Clinical Outcomes

Imagem de Miniatura
Arquivos
art_NOGUEIRA_Follicular_Lymphoma_Refining_Prognostic_Models_and_Impact_of_2022.PDF (468.58 KB)
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
CIG MEDIA GROUP, LP
Autores
Citação
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, v.22, n.2, p.67-75, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Follicular lymphoma (FL) is the most common indolent lymphoma, accounting for 20%-25% of all non-Hodgkin's lymphomas (NHLs). It is a malignancy with variable biologic presentation and heterogeneous clinical outcomes. Several models incorporating clinical laboratory variables and molecular biomarkers are able to predict its prognosis, allowing to stratify patients into different risk groups. However, these prognostic scores should not be used to indicate first-line treatment or risk-adapted therapeutic recommendations. Over the past 5 years, progression of disease within 24 months (POD-24) of first-line chemo-immunotherapy has emerged as a robust adverse prognostic factor, capable of assessing overall survival and identifying high-risk patients with indication for more aggressive therapeutic approaches, such as consolidation based in autologous stem cell transplantation. It should be reinforced that POD-24 is not a baseline measurement, it is based on a post-treatment strategy, and is usually applied to patients with a high tumor burden. The identification of newly diagnosed patients at high risk for disease progression, particularly those with low tumor volume is still a challenge in the context of FL. Therefore, the primary purpose of this review is to provide an overview of the main prognostic models validated to date for FL. Moreover, using these scores, which incorporate clinical and genetic variables, we aim to identify individuals with newly diagnosed FL, advanced disease, and low tumor burden with a high probability of progression or relapse within 24 months of first treatment. Thus, a decision regarding risk-adapted induction therapy could be better stablished for these subset of patients.
Palavras-chave
Follicular lymphoma, Prognostic models, Immunochemotherapy, Risk assessment, Progression of disease within 24 months
URI
https://observatorio.fm.usp.br/handle/OPI/45836
Referências
  1. Bachy E, 2018, BLOOD, V132, P49, DOI 10.1182/blood-2017-11-816405
  2. Barraclough A, 2019, BLOOD, V134, DOI 10.1182/blood-2019-129294
  3. Barrington SF, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-117235
  4. Bitansky G, 2020, LEUKEMIA LYMPHOMA, V61, P2645, DOI 10.1080/10428194.2020.1786554
  5. Brice P, 1997, J CLIN ONCOL, V15, P1110, DOI 10.1200/JCO.1997.15.3.1110
  6. Casulo C, 2015, J CLIN ONCOL, V33, P2516, DOI 10.1200/JCO.2014.59.7534
  7. Cerhan JR, 2017, INT J EPIDEMIOL, V46, P1753, DOI 10.1093/ije/dyx119
  8. Cheson BD, 2007, HEMATOL ONCOL CLIN N, V21, P841, DOI 10.1016/j.hoc.2007.06.011
  9. Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800
  10. Cottereau AS, 2018, BLOOD, V131, P2449, DOI 10.1182/blood-2017-11-816298
  11. Davies A, 2017, LANCET HAEMATOL, V4, pE272, DOI 10.1016/S2352-3026(17)30078-9
  12. Delfau-Larue MH, 2018, BLOOD ADV, V2, P807, DOI 10.1182/bloodadvances.2017015164
  13. Federico M, 2007, HAEMATOLOGICA, V92, P1482, DOI 10.3324/haematol.11502
  14. Freeman CL, 2019, BLOOD, V134, P761, DOI 10.1182/blood.2019000258
  15. Galimberti S, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00528
  16. Gopal AK, 2017, BLOOD, V129, P3037, DOI 10.1182/blood-2016-12-757740
  17. Gritti G, 2017, MEDITERR J HEMATOL I, V9, DOI 10.4084/MJHID.2017.010
  18. Horn H, 2018, HAEMATOLOGICA, V103, P1182, DOI 10.3324/haematol.2017.181024
  19. Huet S, 2018, LANCET ONCOL, V19, P549, DOI 10.1016/S1470-2045(18)30102-5
  20. Jurinovic V, 2016, BLOOD, V128, P1112, DOI 10.1182/blood-2016-05-717355
  21. Kahl BS, 2017, HEMATOL-AM SOC HEMAT, P358, DOI 10.1182/asheducation-2017.1.358
  22. Kelly JL, 2015, J CLIN ONCOL, V33, P1482, DOI 10.1200/JCO.2014.57.5092
  23. Lansigan F, 2019, CANCER MED-US, V8, P165, DOI 10.1002/cam4.1918
  24. Lockmer S, 2020, BRIT J HAEMATOL, V188, P259, DOI 10.1111/bjh.16159
  25. Luminari S, 2014, ANN ONCOL, V25, P442, DOI 10.1093/annonc/mdt562
  26. Luminari S, 2017, HAEMATOL ONCOL, V35, P228, DOI 10.1002/HON.2438
  27. Luminari S, 2019, HEMASPHERE, V3, P82, DOI 10.1097/HS9.0000000000000214
  28. Marcus R, 2017, NEW ENGL J MED, V377, P1331, DOI 10.1056/NEJMoa1614598
  29. Meignan M, 2016, J CLIN ONCOL, V34, P3618, DOI 10.1200/JCO.2016.66.9440
  30. Mir F, 2020, AM J HEMATOL, V95, P1503, DOI 10.1002/ajh.25973
  31. Mozas P, 2021, BRIT J HAEMATOL, V193, P299, DOI 10.1111/bjh.17138
  32. Nooka AK, 2013, ANN ONCOL, V24, P441, DOI 10.1093/annonc/mds429
  33. Pastore A, 2015, LANCET ONCOL, V16, P1111, DOI 10.1016/S1470-2045(15)00169-2
  34. Pott C, 2020, LEUKEMIA, V34, P522, DOI 10.1038/s41375-019-0559-9
  35. Pott C, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-115930
  36. Press OW, 2013, CLIN CANCER RES, V19, P6624, DOI 10.1158/1078-0432.CCR-13-1120
  37. Rimsza LM, 2018, HAEMATOLOGICA, V103, pE151, DOI 10.3324/haematol.2017.175059
  38. SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402
  39. Solal-Celigny P, 2004, BLOOD, V104, P1258, DOI 10.1182/blood-2003-12-4434
  40. Sortais C, 2020, ANN HEMATOL, V99, P1595, DOI 10.1007/s00277-020-04025-2
  41. Strati P, 2020, HAEMATOLOGICA, V105, P1907, DOI 10.3324/haematol.2019.230649
  42. Trotman J, 2018, LANCET ONCOL, V19, P1530, DOI 10.1016/S1470-2045(18)30618-1
  43. Trotman J, 2014, LANCET HAEMATOL, V1, pE17, DOI 10.1016/S2352-3026(14)70008-0
  44. Trotman J, 2011, J CLIN ONCOL, V29, P3194, DOI 10.1200/JCO.2011.35.0736
  45. Wu W, 2020, EVALUATION DIFFERENT
  46. Xu Peng-Peng, 2017, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V25, P426, DOI 10.7534/j.issn.1009-2137.2017.02.021
  47. Yang G, 2020, BLOOD CANCER J, V9, DOI 10.1038/s41408-019-0269-6
  48. Yoo C, 2014, BLOOD RES, V49, P148, DOI 10.5045/br.2014.49.3.148
  49. Zohren F, 2015, BLOOD, V126, P1407, DOI 10.1182/blood-2015-03-630012

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/31
Artigos e Materiais de Revistas Científicas - ODS/03